
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
These 8 drivers of BP control reflect study of high-performing health systems and the strategies that have led to successful large scale hypertension management.
Reference: Brettler JW, Arcila GPG, Aumala T, et al.






